Biomednewsbreaks Transcode Therapeutics, Inc. (NASDAQ: RNAZ) Secures Exclusive Global License To Three Unleash Immuno-Oncolytics Drug Candidates

(MENAFN- Investor Brand Network) TransCode Therapeutics (NASDAQ: RNAZ) announced it has entered into an exclusive, worldwide, fully paid-up royalty-free license agreement with Unleash Immuno Oncolytics, Inc., obtaining rights to develop three drug candidates - UIO-524, UIO-525 and UIO-526 - including all in-licensed and owned rights held by Unleash. Under the agreement, Unleash will receive a one-time payment of 1,136,364 shares of a new series of non-voting convertible preferred stock, convertible into an equal number of common shares and representing 6.8% of TransCode's common stock on a fully diluted basis. The lead candidate, UIO-524, is a next-generation oncolytic adenovirus engineered to selectively replicate in malignant cells and cancer-associated stroma, delivering a multi-cytokine immune-activating payload aimed at treating solid tumors, initially targeting muscle-invasive bladder cancer. The company said the addition of UIO-524 expands its oncology pipeline alongside its lead asset, TTX-MC138, which is advancing toward a Phase 2a clinical trial.

To view the full press release, visit

About TransCode Therapeutics

TransCode Therapeutics is a clinical stage company pioneering immuno-oncology and RNA therapeutic treatments for high risk and advanced cancers. The company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors that overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. In addition, TransCode's portfolio includes other first-in-class therapeutic candidates designed to mobilize the immune system to recognize and destroy cancer cells. For more information, visit .

NOTE TO INVESTORS: The latest news and updates relating to RNAZ are available in the company's newsroom at

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio IBN: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries ; (2) article and editorial syndication to 5,000+ outlets ; (3) enhanced press release enhancement to ensure maximum impact ; (4) social media distribution via IBN to millions of social media followers ; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today's market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire,“Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-

BioMedWire
Austin, Texas

512.354.7000 Office
[email protected]

BioMedWire is powered by IBN

MENAFN03032026000224011066ID1110813382